This site is intended for health professionals only

Published on 9 July 2007

Share this story:
Twitter
LinkedIn

Diabetes drug safety fears questioned

teaser

Safety concerns over the use of thiazolidinediones (TZDs) in patients with heart failure (HF) may be unfounded, say researchers, who found no increased risk in patients treated with TZDs versus other antidiabetic agents.

TZDs are contraindicated in patients with moderate to severe HF because of concerns over weight gain and fluid retention. There have also been reports that TZDs might increase the risk of new-onset HF in diabetic patients.

To investigate further, Dr David Aguilar of Baylor College of Medicine in Texas, USA, and colleagues undertook a retrospective cohort study of patients with HF and diabetes mellitus treated in ambulatory clinics at Veterans



Most read




Latest Issue

Be in the know
Subscribe to Hospital Pharmacy Europe newsletter and magazine
Share this story:
Twitter
LinkedIn